Format

Send to:

Choose Destination

Links from PubMed

Items: 2

1.

PD 0332991

An orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. PD-0332991 selectively inhibits cyclin-dependent kinases (particularly Cdk4/cyclin D1 kinase), which may inhibit retinoblastoma (Rb) protein phosphorylation; inhibition of Rb phosphorylation prevents Rb-positive tumor cells from entering the S phase of the cell cycle (arrest in the G1 phase), resulting in suppression of DNA replication and decreased tumor cell proliferation. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454586&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454586&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49176" NCI Thesaurus) [from PDQ]

MedGen UID:
293741
Concept ID:
C1568660
Organic Chemical; Pharmacologic Substance
2.

Inhibition

MedGen UID:
5809
Concept ID:
C0021469
Molecular Function

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center